Vitiligo Vulgaris
Conditions
Interventions
None listed
Sponsors
Yokoi Kazunori
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with mild to moderate non-segmental vitiligo vulgaris Subjects over the age of 2 at the time of informed consent
Exclusion criteria
Exclusion criteria: Subjects with skin diseases (atopic dermatitis, psoriasis, ichthyosis, cutaneous lymphoma, severe acne, and alopecia areata) excluding Vitiligo Vulgaris Subjects with a history of tape-induced contact dermatitis, mechanical urticaria, or similar conditions. Subjects who have applied topical medications (including prescription and over-the-counter drugs) to the stratum corneum sampling site on the day of sample collection. Subjects for whom stratum corneum sampling is deemed difficult due to wounds or other conditions at the sampling site, as determined by the principal investigator or co-investigators. Subjects who have received antibody-based therapies within the past 120 days. Subjects who have received systemic immunosuppressants, immunomodulators, or live vaccines within the past 28 days. Subjects who have participated in another clinical trial, post-marketing clinical study, or clinical research involving investigational products within 120 days prior to sample collection, or who are currently participating in such studies. Subjects who are pregnant or currently breastfeeding and who may be pregnant. Subjects who wish to be pregnant during this study Subjects considered inappropriate for the study by the principal investigator or co-investigators of the clinical research
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| A comparative analysis of the stratum corneum proteome, plasma proteome, and blood transcriptome will be conducted to identify distinct molecular signatures. | — |
Contacts
Public ContactKazunori Yokoi
The University of Osaka Hospital
Outcome results
None listed